Targeting cancer with small molecule kinase inhibitors

  title={Targeting cancer with small molecule kinase inhibitors},
  author={J. Zhang and P. Yang and N. Gray},
  journal={Nature Reviews Cancer},
  • J. Zhang, P. Yang, N. Gray
  • Published 2009
  • Biology, Medicine
  • Nature Reviews Cancer
  • Deregulation of kinase activity has emerged as a major mechanism by which cancer cells evade normal physiological constraints on growth and survival. To date, 11 kinase inhibitors have received US Food and Drug Administration approval as cancer treatments, and there are considerable efforts to develop selective small molecule inhibitors for a host of other kinases that are implicated in cancer and other diseases. Herein we discuss the current challenges in the field, such as designing selective… CONTINUE READING

    Figures and Topics from this paper.

    Explore Further: Topics Discussed in This Paper

    Targeting cancer with kinase inhibitors.
    • 229
    • Highly Influenced
    • PDF
    Small molecule kinase inhibitors as anti-cancer therapeutics.
    • 45
    • Highly Influenced
    Kinase inhibitors: the road ahead
    • 221
    Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy
    • 182
    Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.
    • 244
    • Highly Influenced
    Type II kinase inhibitors: an opportunity in cancer for rational design.
    • 54
    • Highly Influenced
    Kinase-targeted cancer therapies: progress, challenges and future directions
    • 179


    Publications referenced by this paper.
    Recent advances of MEK inhibitors and their clinical progress.
    • 66
    The selectivity of protein kinase inhibitors: a further update.
    • 2,295
    • PDF